|Tested species reactivity||Human|
|Host / Isotype||Rabbit / IgG|
|Immunogen||Synthetic peptide corresponding to human phosphatidic acid phosphatase type 2 domain containing 2 (PPAPDC2).|
|Purification||Antigen affinity chromatography|
|Storage buffer||PBS with 0.1% BSA|
|Contains||0.08% sodium azide|
|Storage Conditions||-20° C, Avoid Freeze/Thaw Cycles|
|Tested Applications||Dilution *|
|Immunoprecipitation (IP)||Assay Dependent|
|Western Blot (WB)||1:400-1:800|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
A suggested positive control for this product is testislysate.
Upon cell activation Presqualene diphosphate (PSDP)2, a bioactive lipid, rapidly remodels to presqualene monophosphate (PSMP). A newly identified and characterized phosphatase (phosphatidic acid phosphatase domain containing 2 (PPAPDC2)) has recent;y been shown to convert PSDP to PSMP. Unlike the related polyisoprenyl phosphate farnesyl diphosphate (FDP), PSDP has been shown not to be a substrate for type 2 lipid phosphate phosphohydrolases. PSDP phosphatase activity has been identified in activated human neutrophil (PMN) extracts. Recombinant PPAPDC2 displays diphosphate phosphatase activity with substrate preference for PSDP > FDP phosphatidic acid. PPAPDC2 activity is independent of Mg2+ and optimal at pH 7.0–8.0. PPAPDC2 mRNA has been detected in human PMN, and is widely expressed in human tissues. PPAPDC2 expressed inhuman PMN is first lipid phosphate phosphohydrolase identifiedfor PSDP. The regulation of this enzyme and quote;s activity has importantimplications for PMN activation in innate immunity.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.